Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 2010

View Archived Issues

Lundbeck identifies new tachykinin receptor NK3 antagonists as antipsychotic agents

Abbott identifies new alpha4beta2 nicotinic acetylcholine receptor modulators

Aastrom reports interim data of RESTORE-CLI trial in CLI

Chemokine CCR5 receptor antagonist TBR-652 well tolerated in HIV-1-infected patients

Phase II data support potential benefit of bevacizumab in HIV-associated Kaposi's sarcoma

Prime/boost HIV vaccine shows high immunogenicity in healthy volunteers in phase I/II trial

Favorable safety but no response to mapatumumab in refractory colorectal cancer

Ofatumumab shows clinical effects with and without fludarabine in CLL

Bristol-Myers Squibb discovers novel anti-HIV agents

Sigma-Tau reports identification of novel HSP90 inhibitors

AstraZeneca claims novel thrombin inhibitors

Rare Disease Day 2010 focuses attention on orphan drug development

Emory University to begin phase III PROTECT III trial of progesterone in TBI

Roche reports on phase III trial of Avastin in ovarian cancer

FDA releases safety communication on saquinavir

BTG and Paladin complete agreement for DigiFab for digoxin toxicity

Dynavax selects clinical candidate in universal flu vaccine program

Genta initiates once-weekly treatment schedule for tesetaxel

FDA sets tentative new date for review of tesamorelin NDA

EMA approves OncoGenex's development plan for OGX-011

Regulus Therapeutics and GSK establish new microRNA therapeutics collaboration

Once-weekly exenatide NDA review for type 2 diabetes extended by FDA

Sunesis poised to begin phase III voreloxin trial in AML

Agennix reports mortality results from phase II talactoferrin trial in severe sepsis

Astellas withdraws application in Japan for Micardis in type 2 diabetic incipient nephropathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...